Equities

K Pharma Inc

4896:TYO

K Pharma Inc

Actions
  • Price (JPY)600.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.50k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

K Pharma Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through a single segment of research, development, manufacture, and sale of pharmaceuticals, among others. The Company is engaged in induced pluripotent stem cell (iPS) drug discovery business. Neural progenitor cells, the cells that form the basis of nerves, are created from iPS cells, cryopreserved, and then 200000 cells are transplanted by injection into the site of a patient's spinal cord injury. The Company is also engaged in the research, development, manufacture and sale of regenerative medicine products.

  • Revenue in JPY (TTM)500.00m
  • Net income in JPY-221.98m
  • Incorporated2016
  • Employees15.00
  • Location
    K Pharma Inc8F, Tri-seven Roppongi, 7-7-7, RoppongiMINATO-KU 106-0032JapanJPN
  • Phone+81 366293380
  • Fax+81 366293381
  • Websitehttps://kpharma.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
KAINOS Laboratories, Inc.5.06bn637.97m5.21bn144.007.500.7696.891.03152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
Solasia Pharma KK617.00m-1.11bn5.22bn24.00--2.50--8.47-6.61-6.613.6710.780.23014.101.9325,708,330.00-41.51-48.57-47.74-58.8354.7871.01-180.39-300.892.91--0.031---43.5014.1856.36------
Kidswell Bio Corp2.43bn-1.42bn5.24bn41.00--6.23--2.15-40.81-40.8168.7921.350.54151.842.47---31.67-57.41-51.25-81.1342.7555.20-58.49-123.521.70-28.910.7559---12.4318.93-116.31------
MEDRx Co Ltd22.57m-770.66m5.71bn22.00--2.78--253.05-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
Cyfuse Biomedical KK64.79m-645.40m5.74bn21.00--1.87--88.55-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
Noile-Immune Biotech Inc316.82m-1.13bn6.32bn28.00--1.11--19.95-26.14-26.147.32131.420.06080.1818--11,314,930.00-21.69---22.60--99.29---356.68--66.04--0.00---49.37---192.28------
DNA Chip Research Inc490.46m-248.29m6.50bn36.00--8.88--13.26-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.69bn872.00--0.30695.720.2176-49.89-49.898,520.205,115.780.62682.142.70---0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.33-2.57-2.10-153.10--24.62-12.94
Chiome Bioscience Inc682.46m-1.22bn6.76bn51.00--5.46--9.91-24.67-24.6713.7722.000.34414.196.8813,381,650.00-61.51-50.50-79.81-57.3858.4157.53-178.77-224.742.90-513.930.2009--8.1926.241.84------
K Pharma Inc500.00m-221.98m6.96bn15.00--2.42--13.93-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60----------166.34------
CellSeed Inc193.68m-892.21m7.08bn35.00--3.40--36.58-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.16bn109.00--0.9976--1.54-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
Veritas In Silico Inc-100.00bn-100.00bn7.20bn15.00--3.05----------363.52------------------------40.94------101.54--123.38------
Carna Biosciences, Inc.1.63bn-1.15bn7.46bn67.00--1.92--4.59-69.84-69.8496.78226.160.37741.363.3524,267,000.00-26.76-14.45-29.55-16.9589.2290.59-70.91-35.4210.78-312.970.0451--17.2416.5914.57---27.69--
Kohjin Bio Co Ltd-100.00bn-100.00bn7.70bn157.00--2.42----------634.95------------------------1.15--0.4102--20.16--41.20------
Wakamoto Pharmaceutical Co Ltd7.98bn-177.67m8.33bn292.00--0.708935.801.04-5.12-5.12229.89337.150.5252.082.8827,324,600.00-1.17-2.58-1.34-3.0046.9853.08-2.23-4.333.45--0.0085--3.31-4.50-42.041.88-17.490.00
Data as of May 16 2024. Currency figures normalised to K Pharma Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.08%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 04 Apr 20248.80k0.08%
Data from 09 May 2024 - 09 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.